Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bone Marrow and Peripheral Blood Immune Responses Study
NCT05616546Phase 4Recruiting
- Sponsor
- Emory University
- Start
- Oct 2023
- Primary completion
- Dec 2029
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Fluzone Trivalent in influenza, sponsored by Emory University. Primary endpoints: Changes in clonal diversity of B-Cell response to Influenza in blood at Day 365, Changes in clonal diversity of B-Cell response to Influenza in bone marrow at Day 365 and 4 more. Started Oct 2023; status: recruiting.
02
Drugs
Fluzone Trivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05616546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05616546.